Towards the Development of a Targeted Albumin-Binding Radioligand for Theranostic Applications: Synthesis, Radiolabelling and Preliminary In Vivo Studies

GluCAB is a newly synthesised macrocyclic radioligand designed to bind in vivo to albumin (HSA) for the purpose of development as a dual-targeting oncological theranostic agent. Subsequent to its synthesis and ⁶⁴Cu-radiolabelling, this radioligand has show a prolonged circulation time in healthy mice but with appropriate systemic clearance within 24 h. This radioligand meets the criteria to be further investigated for tumour targeting and uptake.